The Pharma Data

NOVEMBER 5, 2020

5, 2020 /PRNewswire/ — Third quarter 2020 revenues increased 32% to $2.29 Third quarter 2020 EYLEA ® U.S. Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07 Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07

Production 52

Production FDA Trials FDA Approval 52

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. 1 Olumiant Prescribing Information, 2020.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

Drug Target Review

JULY 19, 2023

Translating these insights into a licensed vaccine (RTS,S, made by GlaxoSmithKline) took nearly five decades – a glacial pace compared to the recent COVID-19 vaccines. Essentially, Lumen’s antigen design is very similar to RTS,S and R21: a virus-like particle that presents the NANP repeat antigen to the host immune system.

Vaccine 96

Vaccine Engineering Disease Virus 96

The Pharma Data

OCTOBER 28, 2020

28, 2020 /PRNewswire/ — . In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 TARRYTOWN, N.Y. , Regeneron has shared these results with the U.S. There was a 1.08

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

JULY 23, 2021

In December 2020, Chugai obtained development and exclusive commercialisation rights in Japan from Roche, and is working with the Japanese government to ensure an appropriate and timely supply of Ronapreve. As soon as the novel SARS-CoV-2 virus was sequenced in early 2020, we got to work.

Treatment 52

Treatment Virus Clinical Trials Pharmaceuticals 52

The Pharma Data

NOVEMBER 17, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. 3,4,5,6,7). COVID-19 Vaccine AstraZeneca is known as Vaxzevria in Europe. About AstraZeneca.

Vaccine 52

Vaccine Clinical Trials Virus Licensing 52

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

This product was developed by uniQure prior to being licensed to CSL Behring. At the same time, it is understandably important to be able to measure and characterize a treatment’s effect over time. It seems reasonable to assume that there was some hope this would be sufficient for accelerated approval based on this surrogate endpoint.

Therapies 119

Therapies FDA FDA Approval Treatment 119

The Pharma Data

AUGUST 28, 2020

UK signs deals for 90 million virus vaccine doses. The UK remains under the jurisdiction of the European Medicines Agency and its licensing scheme until the end of the Brexit transition period on 31 December 2020. Oxford coronavirus vaccine triggers immune response.

Vaccine 52

Vaccine Immune Response Nurses Government 52

The Pharma Data

JANUARY 5, 2021

Telemedicine isn’t new, but the COVID-19 pandemic has really put the technology front and center, with clinics closing for certain services after state and local governments issued stay-at-home orders to help prevent the spread of the virus. But from March through May of 2020 they jumped to 3,000 to 4,000 visits per day, Keeves said.

Doctors 52

Doctors Pharmacy Vaccine Licensing 52

The Pharma Data

MARCH 11, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. About the Phase 1/2 clinical trial.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

MARCH 29, 2022

13 People at increased risk of exposure to the SARS-CoV-2 virus could also benefit from protection with Evusheld. 1,3 The reduced Fc effector function aims to minimise the risk of antibody-dependent enhancement of disease – a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.20.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

MARCH 25, 2022

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(10) and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function. Evusheld was well-tolerated in the trials.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

DECEMBER 19, 2020

20, 2020 02:44 UTC. Today’s ACIP recommendation follows the December 1, 2020 ACIP recommendation for a Phase 1a rollout in which the first priority for COVID-19 vaccines is given to healthcare personnel treating patients and residents in long-term care facilities. government by the end of December 2020. CAMBRIDGE, Mass.–(

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

MARCH 22, 2021

Casirivimab and imdevimab is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed by Regeneron scientists to block infectivity of SARS-CoV-2, the virus that causes COVID-19. In November 2020, the antibody cocktail was authorised by the U.S.

Clinical Trials 52

Clinical Trials Virus Trials FDA 52

The Pharma Data

APRIL 27, 2021

We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe, as the deadly virus continues to wreak havoc across the continent.” This brings the total number of doses to be delivered to the EU to 600 million. “We said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “To

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 28, 2020

28, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“ BetterLife ” or the “ Company ”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that it has added Mr. Sergei Stetsenko to its Board of Directors to prepare for its growth phase in psychedelic medicines. VANCOUVER, Dec.

Compliance 52

Compliance Licensing Licensing Virus 52

Agency IQ

JANUARY 19, 2024

However, this is actually relatively aligned with the number of new active substances seen prior to and during the first year of the pandemic: 39 in 2020 ; 30 in 2019 ; 42 in 2018 and 35 in 2017. for the years 2020 to 2022. Accelerated assessments accounted for six opinions in 2020, three in 2021, five in 2022, and three in 2023.

Biosimilars 40

Biosimilars FDA Production Treatment 40

The Pharma Data

DECEMBER 20, 2020

20, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. BetterLife also announces that it has engaged GRA Enterprises LLC (the “Consultant”) to provide investor relations services pursuant to a consulting agreement dated December 15, 2020. VANCOUVER, Dec. per share, with the transaction valued at $10 million.

Production 52

Production Clinical Trials Compliance Licensing 52

The Pharma Data

OCTOBER 25, 2020

The UK government’s COVID-19 Vaccine Taskforce and a contract research company called Open Orphan announced a $13 million (£10 million) plan to test investigational COVID-19 vaccines in volunteers who are then intentionally exposed to SARS-CoV-2, the virus that causes COVID-19. They will require regulatory and ethical approval.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

NOVEMBER 2, 2020

GWACHEON, KOREA, November 02, 2020 /24-7PressRelease/ — The trial of Shincheonji Church of Jesus Chairman Man Hee Lee continued on October 21st as the court discussed the alleged violation of the Infectious Disease Prevention Act earlier this year.

Trials 52

Trials Licensing Licensing Virus 52

The Pharma Data

OCTOBER 30, 2020

30, 2020 /PRNewswire/ — The IDMC also recommends continuation of enrollment in the REGN-COV2 outpatient trial. About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. TARRYTOWN, N.Y. ,

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

JANUARY 22, 2021

iosBio , a UK-based biotechnology company, has announced an exclusive worldwide licensing agreement with ImmunityBio , a clinical-stage immunotherapy company, for rights to use iosBio’s OraPro vaccine platform technology to test the oral administration of ImmunityBio’s vaccine candidate.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

DECEMBER 11, 2020

Friday, December 11, 2020. Government to supply doses in 2020 & 2021. Pfizer and BioNTech expect to file a Biologics License Application for possible full regulatory approval in 2021. In July 2020, Pfizer and BioNTech announced an agreement with the HHS and the DoD to meet the U.S.

Vaccine 52

Vaccine Clinical Trials Trials Licensing 52

The Pharma Data

SEPTEMBER 9, 2020

The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval. Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

Codon

MAY 18, 2023

way back in August 2020, and Japan already offers a CRISPR-edited plant in grocery stores: A tomato with boosted levels of GABA, a chemical signal in the brain. Scientists removed Ashanti’s blood cells and inserted a functional copy of the ADA gene via a virus. WIRED just wrote a story about this, but it’s sorta old news.

DNA 52

DNA Engineering Therapies Virus 52

Codon

MAY 18, 2023

way back in August 2020, and Japan already offers a CRISPR-edited plant in grocery stores: A tomato with boosted levels of GABA, a chemical signal in the brain. Scientists removed Ashanti’s blood cells and inserted a functional copy of the ADA gene via a virus. WIRED just wrote a story about this, but it’s sorta old news.

DNA 52

DNA Engineering Therapies Virus 52

The Pharma Data

OCTOBER 29, 2020

29, 2020– Alexion Pharmaceuticals, Inc. NASDAQ:ALXN) today announced financial results for the third quarter of 2020. Non-GAAP diluted EPS for the third quarter of 2020 was $3.24 , a 16 percent increase versus the third quarter of 2019. ” Third Quarter 2020 Financial Highlights. in the prior year.

Clinical Trials 40

Clinical Trials Trials Production Licensing 40

The Pharma Data

DECEMBER 30, 2020

31, 2020 /PRNewswire/ — As COVID-19 cases increase this holiday season, the NYC Test & Trace Corps announced the launch of rapid testing on mobile units to reach more communities in need of testing at no cost. . NEW YORK , Dec.

Nurses 52

Nurses Hospitals Virus Compliance 52

The Pharma Data

JANUARY 12, 2021

. “Patients in our antibody cocktail outpatient clinical trial experienced significant reductions in virus levels and required fewer medical visits for COVID-19, suggesting the therapy can help reduce the current burden on hospitals and healthcare systems,” said George D. Yancopoulos , M.D.,

Government 52

Government Hospitals Virus Clinical Trials 52

Agency IQ

JANUARY 12, 2024

These windows depend on whether the new drug application (NDA) or biologics license application (BLA) is a new molecular entity, and if the application has received standard review (10 months, plus 2 months of administrative time) or priority review (6 months, plus 2 months of administrative time).

FDA 40

FDA Drugs Production Licensing 40

The Pharma Data

APRIL 1, 2021

Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells.

Treatment 52

Treatment Virus Therapies FDA 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. TARRYTOWN, N.Y. , As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

SEPTEMBER 12, 2020

Pfizer Disclosure Notice: The information contained in this release is as of September 12, 2020. For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report on Form 20-F filed with the SEC on March 31, 2020, which is available on the SEC’s website at www.sec.gov.

Vaccine 52

Vaccine Trials Clinical Trials Small Molecule 52

The Pharma Data

JULY 21, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 17, 2020

17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2019 and its Form 10-Q for the quarterly period ended September 30, 2020. TARRYTOWN, N.Y. , “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Therapies 52

The Pharma Data

NOVEMBER 29, 2020

30, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. Response to a two-dose schedule did not show an improvement compared to placebo, which is consistent with the low levels of CMV-neutralizing antibody in the two-dose group as well as with the T cell data reported in June 2020 for the two-dose group. 1 Gilbert C and Boivin G.

Vaccine 52

Vaccine Clinical Trials Disease Therapies 52

The Pharma Data

DECEMBER 14, 2020

14, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. VANCOUVER, Dec.

Bioethics 40

Bioethics Clinical Research Regulations Clinical Trials 40